Merck & Co. has agreed to pay $688 million to settle two shareholder class actions in federal court in Newark claiming it made false and misleading statements about the efficacy of cholesterol-reducing drug Vytorin.
Merck To Pay $688M To End Suits Alleging It Concealed Vytorin Data
New Jersey Law Journal
February 15, 2013
This article requires premium access
This article requires premium access to The New Jersey Law Journal. Please sign in or subscribe to read the full text.